Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2006-11-21
2006-11-21
Prouty, Rebecca E. (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S219000, C435S023000, C435S325000, C435S252300, C514S002600, C530S300000
Reexamination Certificate
active
07138264
ABSTRACT:
The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.
REFERENCES:
patent: 5594106 (1997-01-01), Black et al.
patent: 5830742 (1998-11-01), Black et al.
patent: 5972331 (1999-10-01), Reichert et al.
patent: 5978740 (1999-11-01), Armistead et al.
patent: 6013466 (2000-01-01), Black et al.
patent: WO 99/40182 (1999-08-01), None
Althoff et al. Euro. J. Biochem. 2000, vol. 267, pp. 2624-2631.
Brünger, et al. “Slow-cooling protocols for crystallographic refinement by simulated annealing”,Acta Cryst.A46:585-593 (1990).
Zask, et al. “Inhibition of matrix metalloproteinases: Structure based design”,Current Pharmaceutical Design2:624-661 (1996).
Black, et al. “A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells”,Nature385:729-733 (1997).
Moss, et al .“Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α”,Nature385:733-736 (1997).
Adams, et al. “Cross-validated maximum likelihood enhances crystallographic simulated annealing refinement”,Proc. Natl. Acad. Sci. USA94:5018-5023 (1997).
Brünger, et al. “Crystallography & NMR System: A new software suite for macromolecular structure determination”,Acta Cryst.D54:905-921 (1998).
Maskos, et al. “Crystal structure of the catalytic domain and human tumor necrosis factor-α-converting enzyme”,Proc. Natl. Acad. Sci. USA95:3408-3412 (1998).
Schlöndorff, et al. “Metalloprotease-disintegrins: Modular proteins capable of promoting cell-cell interactions and triggering signals by protein-ectodomain shedding”,Journal of Cell Science112:3603-3617 (1999).
Wang, et al., “Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange™ site-directed mutagenesis”,BioTechniques26:680-682 (1999).
Qi, et al. “Minireview—Tumor necrosis factor-α-induced insulin resistance in adipocytes”,Society for Experimental Biology and Medicine223:128-135 (2000).
Black “Molecules in focus—Tumor necrosis factor-α-converting enzyme”,The International Journal of Biochemistry&Cell Biology34:1-5 (2002).
Bursi, et al. “A three-dimensional quantitative structure-activity relationship study of heparin-binding epidermal growth factor shedding inhibitors using comparative molecular field analysis”,J. Med. Chem.45:781-788 (2002).
Letavic, et al. “Synthesis and biological activity of selective pipecolic acid-based TNF-α Converting Enzyme (TACE) Inhibitors”,Bioorganic&Medicinal Chemistry Letters12:1387-1390 (2002).
Beyer Brian M.
Ingram Richard N.
Orth Peter
Strickland Corey
Meah Mohammad
Prouty Rebecca E.
Schering Corporation
LandOfFree
Modified tumor necrosis factor-alpha converting enzyme and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified tumor necrosis factor-alpha converting enzyme and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified tumor necrosis factor-alpha converting enzyme and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3660158